RTS,S/AS01 vs R21/Matrix-M Malaria Vaccines and Implementation Perspectives in Developing Countries: A Narrative Review

Kiky Martha Ariesaka; Moh Mirza Nuryady

doi:10.2991/978-94-6463-807-3_2

<Previous Article In Volume

Next Article In Volume>

RTS,S/AS01 vs R21/Matrix-M Malaria Vaccines and Implementation Perspectives in Developing Countries: A Narrative Review

Authors

Kiky Martha Ariesaka¹^{, 2}^{, 3}^{, *}, Moh Mirza Nuryady¹^{, 2}^{, 3}

¹Department of Parasitology, Faculty of Medicine, State University of Malang, Malang, Indonesia

²Institute of Parasitology, Department of Biological Science and Pathobiology, Veterinary Medicine University of Vienna, Vienna, Austria

³Department of Biology Education, Faculty of Teacher and Training Education, University of Muhammadiyah Malang, Malang, Indonesia

^*Corresponding author. Email: kiky.martha.fk@um.ac.id

Corresponding Author

Kiky Martha Ariesaka

Available Online 17 September 2025.

DOI: 10.2991/978-94-6463-807-3_2 How to use a DOI?
Keywords: Malaria Vaccines; Indonesia; RTS; S/AS01; R21/Matrix-M; Vaccine Implementation Challenges
Abstract: Malaria remains a significant public health challenge in Indonesia, particularly in regions like Papua and Nusa Tenggara Timur (NTT). Despite various control efforts, the country continues to struggle with high malaria incidence, highlighting the need for new interventions. The recent WHO approval of malaria vaccines RTS,S/AS01 and R21/Matrix-M offers a potential game-changer in the fight against malaria. This review aims to assess the prospects and challenges of integrating these vaccines into Indonesia’s national malaria control strategy, including an in-depth comparison of the two WHO-approved vaccines. A comprehensive search of scientific databases and grey literature was conducted, focusing on studies published between 2015 and 2024. The review included articles, government reports, and WHO documents, analyzing data on vaccine efficacy, safety, and implementation challenges specific to Indonesia’s unique epidemiological landscape. The findings indicate that while the high efficacy of these vaccines against Plasmodium falciparum (P. falciparum) presents a promising opportunity, the presence of other Plasmodium species, particularly P. vivax, in Indonesia requires further research. Additionally, significant logistical challenges, such as cold chain management and healthcare infrastructure limitations, pose obstacles to widespread vaccine implementation. The conclusion, while the integration of malaria vaccines could significantly advance Indonesia’s goal of malaria elimination by 2030, successful implementation will require tailored strategies addressing the country’s specific challenges. Future research and pilot studies in Indonesia are essential to evaluate vaccine efficacy in the local context and to develop effective deployment strategies.
Copyright: © 2025 The Author(s)
Open Access: Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

<Previous Article In Volume

Next Article In Volume>

Volume Title: Proceedings of the Malang International Conference in Medical and Health Sciences (MICROMEDHS 2024)
Series: Advances in Health Sciences Research
Publication Date: 17 September 2025
ISBN: 978-94-6463-807-3
ISSN: 2468-5739
DOI: 10.2991/978-94-6463-807-3_2 How to use a DOI?
Open Access: Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Cite this article

ris enw bib

TY  - CONF
AU  - Kiky Martha Ariesaka
AU  - Moh Mirza Nuryady
PY  - 2025
DA  - 2025/09/17
TI  - RTS,S/AS01 vs R21/Matrix-M Malaria Vaccines and Implementation Perspectives in Developing Countries: A Narrative Review
BT  - Proceedings of the Malang International Conference in Medical and Health Sciences (MICROMEDHS 2024)
PB  - Atlantis Press
SP  - 7
EP  - 30
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-807-3_2
DO  - 10.2991/978-94-6463-807-3_2
ID  - Ariesaka2025
ER  -

download .riscopy to clipboard